SCHEMBL131122

SCHEMBL131122

Cc1cccc(-c2nn(C(C)c3oc4ccccc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 14/20 0.78
PIK3CG P48736 10/20 0.71
CSNK1E P49674 2/20 0.71
PIK3R1 P27986 1/20 0.71
SRC P12931 9/20 0.54
PIK3CB P42338 7/20 0.46
ABL1 P00519 7/20 0.45
PIK3CA P42336 6/20 0.45
EGFR P00533 5/20 0.45
HCK P08631 5/20 0.45
KDR P35968 5/20 0.45
MTOR P42345 5/20 0.45
EPHB4 P54760 5/20 0.45
PRKDC P78527 5/20 0.45
PI4KB Q9UBF8 4/20 0.45
BMPR1B O00238 1/20 0.42
RIPK2 O43353 1/20 0.42
STK16 O75716 1/20 0.42
STK10 O94804 1/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131212 0.94 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL131196 0.93 PIK3CD (0.77) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL128964 0.92 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL130978 0.92 PIK3CD (0.83) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL30012572 0.92 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL130921 0.92 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL11224 0.92 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL29651612 0.92 PIK3CD (0.78) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL13783 0.92 PIK3CD (0.75) PIK3CDPIK3CGCSNK1EPIK3R1SRC
SCHEMBL29651597 0.92 PIK3CD (0.75) PIK3CDPIK3CGCSNK1EPIK3R1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885CSNK1E 109/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3CG 126/4885CSNK1E 98/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885CSNK1E 109/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885CSNK1E 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.